Literature DB >> 29657681

Outcomes of Isolated Antenatal Hydronephrosis at First Year of Life.

Mutaz Orabi1, Sameh Abozaid1, Bahauddin Sallout2, Amani Abu Shaheen3, Humariya Heena3, Abdulrahman Al Matary1.   

Abstract

OBJECTIVES: To compare the grade of hydronephrosis between the antenatal and first postnatal ultrasound (US) and their clinical outcomes.
METHODS: This retrospective study included all cases of isolated hydronephrosis detected by antenatal US from August 2005 to February 2011. Hydronephrosis was classified based on the standard criteria into mild, moderate, or severe. Cases associated with other major congenital anomalies were excluded. All patients were followed-up postnatally and outcomes available were analyzed at one year of age.
RESULTS: A total of 105 cases were included out of which 83 (79.0%) were males and 22 (20.9%) were females with a median gestational age of 38 weeks. First postnatal US of 105 cases showed that 20 (19.0%) were free of hydronephrosis, 39 (37.1%) had mild, 29 (27.6%) moderate, and 17 (16.1%) had severe hydronephrosis. Half (50.4%) of hydronephrosis cases improved in their clinical presentation while 13.3% showed deterioration and 36.3% remained the same. Almost half of all cases (52 cases) were diagnosed by US at the end of first year without any effect on renal function.
CONCLUSIONS: Antenatal and postnatal US are sensitive tools for detecting hydronephrosis as well as for postnatal counseling. Fetal anatomy US is usually done at 18 weeks gestation and if this reveals any evidence of hydronephrosis, the patient is followed according to the severity. Postnatal US is not done routinely for cases where hydronephrosis resolves completely during pregnancy. Although newborns with antenatal hydronephrosis due to secondary causes are at greater risk for renal impairment, surgical intervention reserves renal function.

Entities:  

Keywords:  Amniotic Fluid Index; Antenatal Ultrasound; Chronic Kidney Disease; Hydronephrosis; MAG3; Ultrasound Imaging; Urinary Tract Infection

Year:  2018        PMID: 29657681      PMCID: PMC5889835          DOI: 10.5001/omj.2018.24

Source DB:  PubMed          Journal:  Oman Med J        ISSN: 1999-768X


  6 in total

1.  Antenatal minimal hydronephrosis: is its follow-up an unnecessary cause of concern?

Authors:  L J Harding; P S Malone; D G Wellesley
Journal:  Prenat Diagn       Date:  1999-08       Impact factor: 3.050

2.  Does every patient with prenatal hydronephrosis need voiding cystourethrography?

Authors:  E B Yerkes; M C Adams; J C Pope; J W Brock
Journal:  J Urol       Date:  1999-09       Impact factor: 7.450

3.  The magnitude of fetal renal pelvic dilatation can identify obstructive postnatal hydronephrosis, and direct postnatal evaluation and management.

Authors:  Douglas E Coplen; Paul F Austin; Yan Yan; Valerie M Blanco; Jeffrey M Dicke
Journal:  J Urol       Date:  2006-08       Impact factor: 7.450

4.  Antenatal hydronephrosis as a predictor of postnatal outcome: a meta-analysis.

Authors:  Richard S Lee; Marc Cendron; Daniel D Kinnamon; Hiep T Nguyen
Journal:  Pediatrics       Date:  2006-08       Impact factor: 7.124

Review 5.  The Society for Fetal Urology consensus statement on the evaluation and management of antenatal hydronephrosis.

Authors:  Hiep T Nguyen; C D Anthony Herndon; Christopher Cooper; John Gatti; Andrew Kirsch; Paul Kokorowski; Richard Lee; Marcos Perez-Brayfield; Peter Metcalfe; Elizabeth Yerkes; Marc Cendron; Jeffrey B Campbell
Journal:  J Pediatr Urol       Date:  2010-04-15       Impact factor: 1.830

6.  Incidental vesicoureteral reflux in neonates with antenatally detected hydronephrosis and other renal abnormalities.

Authors:  J M Zerin; M L Ritchey; A C Chang
Journal:  Radiology       Date:  1993-04       Impact factor: 11.105

  6 in total
  1 in total

1.  Validation of "urinary tract dilation" classification system: Correlation between fetal hydronephrosis and postnatal urological abnormalities.

Authors:  Hui Zhang; Lijuan Zhang; Nan Guo
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.817

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.